4//SEC Filing
DiBiase Mary 4
Accession 0001628280-23-032065
CIK 0001501697other
Filed
Sep 11, 8:00 PM ET
Accepted
Sep 12, 4:04 PM ET
Size
5.3 KB
Accession
0001628280-23-032065
Insider Transaction Report
Form 4
DiBiase Mary
Chief Operating Officer
Transactions
- Sale
Common Stock
2023-09-08$1.25/sh−2,642$3,300→ 147,894 total
Footnotes (3)
- [F1]The reported transaction was effected pursuant to a Rule 10b5-1 trading plan.
- [F2]The price reported is a weighted average price. These shares were sold in multiple transactions ranging from $1.22 to $1.255, inclusive. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- [F3]Of the shares of common stock reported, 74,046 shares represent restricted stock units.
Documents
Issuer
X4 Pharmaceuticals, Inc
CIK 0001501697
Entity typeother
Related Parties
1- filerCIK 0001880179
Filing Metadata
- Form type
- 4
- Filed
- Sep 11, 8:00 PM ET
- Accepted
- Sep 12, 4:04 PM ET
- Size
- 5.3 KB